# EDGAR Filing Document

**Accession Number:** 0001340243
**File Stem:** 0001628280-23-008204
**Filing Date:** 2023-3
**Character Count:** 51761
**Document Hash:** 1ec5ee70ba29f124474d59728f17085a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-008204.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0001628280-23-008204

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 36

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MorphoSys AG
- **CENTRAL INDEX KEY:** 0001340243
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38455
- **FILM NUMBER:** 23737391

**BUSINESS ADDRESS:**
- **STREET 1:** SEMMELWEISSTR. 7
- **CITY:** PLANEGG
- **STATE:** 2M
- **ZIP:** 82152
- **BUSINESS PHONE:** 49 89 89927-0

**MAIL ADDRESS:**
- **STREET 1:** SEMMELWEISSTR. 7
- **CITY:** PLANEGG
- **STATE:** 2M
- **ZIP:** 82152

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MORPHOSYS AG
- **DATE OF NAME CHANGE:** 20050929

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March, 2023**

**COMMISSION FILE NUMBER 001-38455**

**MorphoSys AG**

**Semmelweisstrasse 7**

**82152 Planegg**

**Germany**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ⌧ Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

------

On March 15, 2023, MorphoSys AG (the "Company") issued a press release with the full year 2022 financial results attached hereto as Exhibit 99.1. On March 16, 2023, MorphoSys AG, held its YE 2022 results conference call attached hereto as Exhibit 99.2.

**<u>Exhibits</u>**

99.1&nbsp;&nbsp;&nbsp;&nbsp;<u>[MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update](a230316_exhibit991.htm)</u>

99.2&nbsp;&nbsp;&nbsp;&nbsp;<u>[FY 2022 Results & Business Update](a230316_exhibit992.htm)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**&nbsp;&nbsp;&nbsp;&nbsp;**MORPHOSYS AG (Registrant)

Date: March 16, 2023&nbsp;&nbsp;&nbsp;&nbsp;By:&nbsp;&nbsp;&nbsp;&nbsp;<u>/s/ i.A. Kristina Grötsch</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Kristina Grötsch

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp;&nbsp;&nbsp;Senior Specialist Investor Relation

&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;By:&nbsp;&nbsp;&nbsp;&nbsp;<u>/s/ i.A. Isabelle Degbegni</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name: Isabelle Degbegni

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp;&nbsp;&nbsp;Director Investor Relations &nbsp;&nbsp;&nbsp;&nbsp;

## Exhibit 99.1

![](a230316_exhibit991001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Page 1 Media Release Planegg/Munich, Germany, March 15, 2023 MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update – Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 – Monjuvi® U.S. net product sales of US$25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$89.4 million (€ 84.9 million) for the full year of 2022 – € 907.2 million in cash and other financial assets as of December 31, 2022 – Conference call and webcast (in English) tomorrow, March 16, 2023, at 1:00pm CET (12:00pm GMT/8:00am EDT) MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022. "2022 was a defining year for MorphoSys. We made advances in our pipeline by progressing our Phase 3 clinical trials, including pelabresib in myelofibrosis and tafasitamab in lymphomas. We also out-licensed highly promising, early and mid-stage product candidates, enabling us to concentrate exclusively on our work in oncology," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys. "In 2023, we will continue to prioritize the Phase 3 study of pelabresib in myelofibrosis, on our way to sharing topline data in early 2024 and exploring its potential use in other myeloid diseases. We remain steadfast in our commitment to developing and delivering novel therapies that are safer and more effective for cancer patients, and we look forward to the future." Pelabresib Highlights: On January 9, 2023, MorphoSys announced that topline data from the ongoing Phase 3 MANIFEST-2 study are expected to be available in early 2024. MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis. The latest analyses include longer-term data showing durable improvements in both spleen volume and symptom score beyond 24 weeks, with pelabresib plus ruxolitinib in JAK inhibitor-naïve patients. Monjuvi/Minjuvi® Highlights: Monjuvi (tafasitamab-cxix) U.S. net product sales of US$25.3 million (€ 24.7 million) for the fourth quarter 2022 (Q4 2021: US$23.6 million (€ 20.5 million)) and US$89.4 million (€ 84.9 million) for the full year of 2022 (2021: US$79.1 million (€ 66.9 million)). Minjuvi royalty revenue of € 0.7 million for sales outside of the U.S. in the fourth quarter 2022 and € 3.0 million for the full year of 2022. Tafasitamab Data: At the ASH conference in December 2022, final safety and efficacy results from firstMIND, a Phase 1b, open-label, randomized safety study combining tafasitamab or tafasitamab plus lenalidomide with standard R-CHOP were presented, showing no new safety signals and providing additional information on progression-free survival at 24 months for patients with

------

![](a230316_exhibit991002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Page 2 newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with tafasitamab plus lenalidomide and R-CHOP. Two additional analyses also suggested that sensitive assays to detect minimal residual disease have prognostic value at the end of first-line therapy. Corporate Developments: On December 6, 2022, MorphoSys' fully owned subsidiary Constellation Pharmaceuticals, Inc. entered into a global licensing agreement with Novartis to research, develop, and commercialize its preclinical inhibitors of a novel cancer target. Under the terms of the agreement, Novartis will assume full responsibility for all subsequent research, development, and commercialization activities for the program. As part of the agreement, MorphoSys received an immediate upfront payment of US$23 million. On achievement of development, regulatory, and commercial milestones, MorphoSys will be eligible to receive milestone payments from Novartis in addition to mid-single to low-double-digit royalties on program net sales. On December 20, 2022, MorphoSys announced that Sung Lee, the company's Chief Financial Officer and Management Board member, has decided to leave MorphoSys to move back to California. His last day with MorphoSys will be March 17, 2023. Significant Events After the End of the Fourth Quarter of 2022: On March 2, 2023, MorphoSys announced that it will stop work and operations on its pre- clinical research programs to optimize its cost structure. MorphoSys will reduce its workforce at the company's headquarters in Planegg, Germany, by approximately 17%. This action, along with other steps taken over the past year, enables MorphoSys to focus resources on its mid- to late-stage oncology pipeline. On March 14, 2023, MorphoSys announced that Lucinda Crabtree, Ph.D., will join as Chief Financial Officer and member of the Management Board. She will start in the third quarter 2023 at the latest. Charlotte Lohmann was appointed as Chief Legal Officer on March 1, 2023 and will serve as a member of MorphoSys' Management Board ad interim. Financial Results for the Fourth Quarter of 2022 (IFRS): Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021. This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022. in € million\* Q4 2022 Q3 2022 Q4 2021 Q-Q Δ Y-Y Δ Total revenues 81.6 95.8 52.9 (15) % 54 % Monjuvi product sales 24.7 21.9 20.5 13 % 20 % Royalties 29.1 29.7 23.2 (2) % 25 % Licenses, milestones and other 27.9 44.1 9.3 (37) % > 100% \* Differences due to rounding. Cost of Sales: In the fourth quarter of 2022, cost of sales was € 15.4 million compared to € 9.5 million for the same period in 2021. The fourth quarter of 2022 includes € 5.1 million of expenses related to activities to optimize the Monjuvi supply chain. Research and Development (R&D) Expenses: In the fourth quarter 2022, R&D expenses were € 94.0 million compared to € 87.0 million for the same period in 2021. The increase is primarily due to clinical trial material expenses in the fourth quarter 2022 partially offset by lower personnel costs.

------

![](a230316_exhibit991003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Page 3 Selling, General and Administrative (SG&A) Expenses: Selling expenses in the fourth quarter 2022 were € 23.0 million compared to € 32.5 million for the same period in 2021. The decrease was driven by higher investments in 2021 made into the commercial organization, the first full year after the Monjuvi launch. General and administrative (G&A) expenses amounted to € 17.5 million compared to € 18.2 million for the same period in 2021. Operating Loss: Operating loss amounted to € 68.4 million in the fourth quarter 2022 compared to a loss of € 325.0 million for the same period in 2021. The lower year-over-year operating loss was primarily driven by the impairment of goodwill amounting to € 230.7 million recognized in the fourth quarter 2021. Consolidated Net Profit / Loss: For the fourth quarter 2022, consolidated net profit was € 329.4 million compared to a net loss of € 381.0 million for the same period in 2021. The consolidated net profit in the fourth quarter 2022 was driven mainly by the recognition of finance income triggered by the reduction in financial liabilities from collaborations. Financial Results for the Full Year 2022 (IFRS): Total Revenues for the full year 2022 were € 278.3 million compared to € 179.6 million in 2021. The increase resulted mainly from higher revenues from licenses due to the out- licensing agreements with HI-Bio and Novartis. Royalties in 2022 include € 3.0 million from the sale of Minjuvi outside of the U.S. by our partner Incyte and € 96.9 million from Tremfya® sales which is fully passed on to Royalty Pharma. in € million\* 2022 2021 Y-Y Δ Total revenues 278.3 179.6 55 % Monjuvi product sales 84.9 66.9 27 % Royalties 99.9 65.6 52 % Licenses, milestones and other 93.5 47.2 98 % \* Differences due to rounding. Cost of Sales: For the full year 2022, cost of sales were € 48.6 million compared to € 32.2 million in 2021. The increase was primarily driven by higher sales of Monjuvi in the U.S. and Minjuvi outside of the U.S. and expenses related to activities to optimize the Monjuvi supply chain. R&D Expenses: For the full year 2022, R&D expenses were € 297.8 million compared to € 225.2 million in 2021. The R&D expenses increased primarily due to higher development activity and the inclusion of expenses from the Constellation acquisition since Q3 2021. SG&A Expenses: Selling expenses for the full year 2022 were € 92.4 million compared to € 121.5 million in 2021. The decrease was primarily driven by higher investments made into the commercial organization in 2021, the first full year after the Monjuvi launch. G&A expenses amounted to € 60.1 million for 2022 compared to € 78.3 million in 2021. The decrease was driven primarily by the transaction costs related to the Constellation and Royalty Pharma agreements in 2021. Operating Loss: Operating loss amounted to € 220.7 million for the full year 2022 compared to a loss of € 508.3 million in 2021. The lower year-over-year operating loss was primarily driven by the impairment of goodwill amounting to € 230.7 million recognized in 2021. Consolidated Net Loss: For the full year 2022, consolidated net loss was € 151.1 million compared to a net loss of € 514.5 million in 2021. The lower consolidated net loss in 2022

------

![](a230316_exhibit991004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Page 4 was driven mainly by the recognition of finance income triggered by the reduction in financial liabilities from collaborations. Cash and Other Financial Assets: As of December 31, 2022, the Company had cash and other financial assets of € 907.2 million compared to € 976.9 million on December 31, 2021. Number of shares: The number of shares issued totaled 34,231,943 on December 31, 2022, no change compared to December 31, 2021. Full Year 2023 Financial Guidance: Amounts in million 2023 Financial Guidance 2023 Guidance Insights Monjuvi U.S. net product sales US$80m to 95m 100% of Monjuvi U.S. net product sales are recorded on MorphoSys' income statement and related profit/loss is split 50/50 between MorphoSys and Incyte. Gross margin for Monjuvi U.S. net product sales 75% to 80% 100% of Monjuvi U.S. product cost of sales are recorded on MorphoSys' income statement and related profit/loss is split 50/50 between MorphoSys and Incyte. R&D expenses € 290m to 315m 2023 anticipated to be incrementally higher than 2022 due to the expansion of the pelabresib development program. SG&A expenses € 140m to 155m 45% to 50% of mid-point of SG&A expenses represent Monjuvi U.S. selling costs of which 100% are recorded in MorphoSys' income statement. Incyte reimburses MorphoSys for half of these selling expenses. Additional information related to 2023 Financial Guidance: • Tremfya royalties will continue to be recorded as revenue without any cost of sales in MorphoSys' income statement. These royalties, however, will not contribute any cash to MorphoSys, as 100% of the royalties will be passed on to Royalty Pharma. • MorphoSys anticipates receiving royalties for Minjuvi sales outside of the U.S. • MorphoSys does not anticipate any significant cash-accretive revenues from the achievement of milestones in 2023. • MorphoSys anticipates sales of commercial and clinical supply of tafasitamab outside of the U.S. to its partner Incyte. Revenue from this supply is recorded in the "Licenses, milestones and other" category in MorphoSys' income statement. These sales result in a zero gross profit/margin. As such, MorphoSys does not provide guidance for these sales Operational Outlook: The following events and development activities planned for 2023 and beyond include the following: • full patient enrollment for the pivotal Phase 3 study (MANIFEST-2) of pelabresib in myelofibrosis (MF) in 2023 with topline results anticipated in early 2024;

------

![](a230316_exhibit991005.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Page 5 • primary analysis data from the Phase 3 study (inMIND) of tafasitamab in patients with indolent lymphoma (r/r FL/MZL) in 2024; • primary analysis data from the pivotal Phase 3 study (frontMIND) of tafasitamab in previously untreated DLBCL in the second half of 2025. MorphoSys Group Key Figures (IFRS, end of financial year: December 31, 2022) in € million Q4 2022 Q4 2021 Δ 2022 2021 Δ Revenues 81.6 52.9 54 % 278.3 179.6 55 % Product Sales 24.7 20.5 20 % 84.9 66.9 27 % Royalties 29.1 23.2 25 % 99.9 65.6 52 % Licenses, Milestones and Other 27.9 9.3 >100% 93.5 47.2 98 % Cost of Sales (15.4) (9.5) 62 % (48.6) (32.2) 51 % Gross Profit 66.2 43.4 53 % 229.6 147.4 56 % Total Operating Expenses (134.6) (368.4) (63) % (450.4) (655.8) (31) % Research and Development (94.0) (87.0) 8 % (297.8) (225.2) 32 % Selling (23.0) (32.5) (29) % (92.4) (121.5) (24) % General and Administrative (17.5) (18.2) (4) % (60.1) (78.3) (23) % Impairment of Goodwill — (230.7) (100) % — (230.7) (100) % Operating Profit / (Loss) (68.4) (325.0) (79) % (220.7) (508.3) (57) % Other Income (7.8) 3.4 >(100)% 12.0 8.2 46 % Other Expenses 7.4 (1.7) >(100)% (15.6) (6.4) >100% Finance Income 325.0 (2.7) >(100)% 412.1 96.6 >100% Finance Expenses 249.5 (89.0) >(100)% (165.9) (181.5) (9) % Income from Reversals of Impairment Losses / (Impairment Losses) on Financial Assets 0.4 (0.2) >(100)% — 0.3 (100) % Share of Loss of Associates accounted for using the Equity Method (4.0) — n/a (4.3) — n/a Income Tax Benefit / (Expenses) (172.7) 34.4 >(100)% (168.6) 76.6 >(100)% Consolidated Net Profit / (Loss) 329.4 (381.0) >(100)% (151.1) (514.5) (71) % Earnings per Share, Basic and Diluted (in €) — (11.16) n/a (4.42) (15.40) (71) % Earnings per Share, Basic 9.64 — n/a — — n/a Earnings per Share, Diluted 8.93 — n/a — — n/a Cash and other financial assets (end of period) 907.2 976.9 \* (7) % 907.2 976.9 \* (7) % \* Value as of December 31, 2021

------

![](a230316_exhibit991006.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Page 6 MorphoSys will hold its conference call and webcast tomorrow, March 16, 2023, at 1:00pm CET (12:00pm GMT/8:00am EDT) to present the results for the fourth quarter and the full year 2022. Participants for the conference call and webcast may pre-register and will receive dedicated dial-in details to easily and quickly access the call: https://services.choruscall.it/DiamondPassRegistration/register?confirmationNumber=347823 8&linkSecurityString=469447192 Please dial in 10 minutes before the beginning of the conference. A live webcast and slides will be made available at the Investors section under "Events & Conferences" on MorphoSys' website, https://www.morphosys.com and after the call, a slide- synchronized audio replay of the conference will be available at the same location. Consolidated Financial Statements 2022 (IFRS) are available for download at: https://www.morphosys.com/en/investors/financial-information About MorphoSys At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we develop and deliver innovative medicines, aspiring to redefine how cancer is treated. MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts. To learn more, visit us at www.morphosys.com and follow us on Twitter and LinkedIn. About Pelabresib Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. Pelabresib is being investigated as a treatment for myelofibrosis and has not yet been evaluated or approved by any regulatory authorities. About Monjuvi (tafasitamab-cxix) Monjuvi® (tafasitamab-cxix) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody- Dependent Cellular Phagocytosis (ADCP). In the United States, Monjuvi® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). In Europe, Minjuvi® (tafasitamab) received conditional marketing authorization in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials. Monjuvi® and Minjuvi® are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi® in the U.S., and marketed by Incyte under the brand name Minjuvi® in Europe, the UK and Canada. Tremfya® is a registered trademark of Janssen Biotech, Inc. XmAb® is a registered trademark of Xencor, Inc.

------

![](a230316_exhibit991007.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Page 7 Forward Looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward- looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward- looking statements, unless specifically required by law or regulation. For more information, please contact: Media Contacts: Thomas Biegi Vice President Tel.: +49 (0)89 / 899 27 26079 thomas.biegi@morphosys.com Investor Contacts: Dr. Julia Neugebauer Head of Investor Relations Tel: +49 (0)89 / 899 27 179 julia.neugebauer@morphosys.com Eamonn Nolan Director, Communications Tel: +1 617-548-9271 eamonn.nolan@morphosys.com

------

## Exhibit 99.2

![](a230316_exhibit992001.jpg)

FY 2022 Results & Business Update March 16, 2023

------

![](a230316_exhibit992002.jpg)

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as well as the commercial performance of Monjuvi. The words "anticipate", "believe", "estimate", "expect", "intend", "may", "plan", "predict", "project", "would", "could", "potential", "possible", "hope" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as well as the commercial performance of Monjuvi, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) or any other regulatory authority (except for tafasitamab/Monjuvi® and tafasitamab/Minjuvi®). There is no guarantee any investigational product will be approved by regulatory authorities. Monjuvi® and Minjuvi® are registered trademarks of MorphoSys AG. Forward-Looking Statements© MorphoSys – FY 2022 results 2

------

![](a230316_exhibit992003.jpg)© MorphoSys – FY 2022 results 3 Q&A Jean-Paul Kress, Sung Lee, Tim Demuth, Joe Horvat (General Manager, U.S.) Financial Results & Guidance Sung Lee, Chief Financial Officer (CFO) Development Update Tim Demuth, M.D., Ph.D., Chief Research & Development Officer (CR&DO) 04 03 01 Agenda 02 2022 Highlights & Outlook Jean-Paul Kress, M.D., Chief Executive Officer (CEO)

------

![](a230316_exhibit992004.jpg)

Jean-Paul Kress, M.D. CEO 2022 Highlights & Outlook 01© MorphoSys – FY 2022 results

------

![](a230316_exhibit992005.jpg)

OUR AMBITION Two novel cancer medicines available to patients by 2025 Strategic Focus on Oncology Supported by Strong Financial Position 5© MorphoSys – FY 2022 results FOCUSED STRATEGY • Hematology-oncology focus FINANCIAL STRENGTH • Strong balance sheet • Disciplined capital allocation HEMATOLOGY- ONCOLOGY EXPERTISE • Proven track record in late-stage development and regulatory approvals • Established commercial and sales team BEST-IN-CLASS PIPELINE • Two late-stage and one mid-stage programs

------

![](a230316_exhibit992006.jpg)

Topline data from Phase 3 MANIFEST-2 study expected in early 2024 Pelabresib Has Potential to Improve Standard of Care in Myelofibrosis Only ~50% of patients see adequate control and responses are limited in their duration with JAK inhibitors Myelofibrosis is a Debilitating Disease with Limited Treatment Options Phase 2 Results Suggest Deep and Durable Improvements in Spleen Volume and Symptom Score At and Beyond 24 Weeks\* SVR35 AT WK 24: 68%\* (57/84) TSS50 AT WK 24: 56%\* (46/82) Spleen Volume Anemia & Transfusion Dependence Bone Marrow Fibrosis Constitutional Symptoms (night sweats, itching and fatigue) \*Mascarenhas J, et al. ASH 2022. Abstract 238. 6© MorphoSys – FY 2022 results

------

![](a230316_exhibit992007.jpg)© MorphoSys – FY 2022 results 7 Monjuvi® Serves and Has Potential to Address Important DLBCL Patient Needs Across Second- and First-Line Settings $25.3MM +7% YoY +8% demand Q4 2022 U.S. Sales Q3'20 Q4'20 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 >70% Community <30% Academic SoC Growth 1,420 sites of care Continued education to evolve prescribing pattern Improving Persistence Monjuvi® (tafasitamab-cxix) is approved under accelerated approval by the U.S. FDA in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT; DLBCL: diffuse large B-cell lymphoma Only out-patient, in-practice immunotherapy approved for 2L+ adult NTE DLBCL in combination with lenalidomide Phase 3 frontMIND study in first-line DLBCL progressing very well, topline data available in H2 2025 Largest Opportunity Yet to Come

------

![](a230316_exhibit992008.jpg)

8 OPTIMIZED COST STRUCTURE + Pivotal trials: - Ianalumab (Novartis) - Abelacimab (Anthos Therapeutics) - Setrusumab (Ultragenyx/Mereo) PARTNERED PROGRAMS ADVANCED + Reduction of selling expenses + Stopped pre-clinical research work and operations FOCUSED RESOURCES + Lucinda Crabtree, Ph.D., to join as CFO in Q3 2023 NEW CHIEF FINANCIAL OFFICER + Novartis license deal for: - Preclinical inhibitors of cancer target + HI-Bio license deal for: - Felzartamab - MOR210 2022 and Recent Developments Support Continued Progress© MorphoSys – FY 2022 results

------

![](a230316_exhibit992009.jpg)

Development Update 02 Tim Demuth, M.D., Ph.D. CR&DO© MorphoSys – FY 2022 results

------

![](a230316_exhibit992010.jpg)

Monjuvi® (tafasitamab-cxix) is approved under accelerated approval by the U.S. FDA in combination with lenalidomide for the treatment of adult patients with relapsed or refractory ]DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT; r/r DLBCL: relapsed/refractory diffuse large B-cell lymphoma. r/r FL / MZL: relapsed/refractory Follicular Lymphoma or Marginal Zone Lymphoma \*Trial sponsored by Pfizer Best-In-Class Mid- to Late-Stage Oncology Pipeline 10 A S S E T P A R T N E R T A R G E T D I S E A S E A R E A P H A S E 1 P H A S E 2 P H A S E 3 M A R K E T Tafasitamab Incyte CD19 r/r DLBCL 1L DLBCL (frontMIND) r/r FL/MZL (inMIND) r/r DLBCL (with TTI-622)\* Pelabresib BET 1L Myelofibrosis (MANIFEST-2) 1L/2L Myelofibrosis (MANIFEST) Tulmimetostat (CPI-0209) EZH2 Solid tumors/Lymphomas trial not yet initiated© MorphoSys – FY 2022 results

------

![](a230316_exhibit992011.jpg)

11 STUDY POPULATION TREATMENT ARM/COHORT ENDPOINTSDESIGN/SIZE Topline data from MANIFEST-2 study expected in early 2024 Placebo + Ruxolitinib Pelabresib + Ruxolitinib JAK-inhibitor-naïve myelofibrosis patients Primary: SVR35 at 24 weeks Key Secondary: TSS50 at 24 weeks Double-Blind Randomization N=400 Phase 3 MANIFEST-2 Study Investigating Pelabresib as a First-Line Myelofibrosis Treatment© MorphoSys – FY 2022 results

------

![](a230316_exhibit992012.jpg)

Longer-Term Data Suggest Deep and Durable Improvements in Spleen Volume and Symptom Score with Pelabresib Phase 2 MANIFEST trial results presented at ASH 2022 12 SPLEEN VOLUME CHANGE OVER TIME TSS CHANGE OVER TIME 0 12 24 36 48 60 84 Week N 82 79 71 64 57 -100 -50 0 50 100 150 200 % C h a n g e F ro m B a se lin e Mean SVR35 AT WK 24: 68% (57/84) TSS50 AT WK 24: 56% (46/82) The most common hematologic adverse events (AE) were thrombocytopenia (55%, grade ≥3: 18%) and anemia (43%, grade ≥3: 34%) The most common nonhematologic AEs of any grade were diarrhea (43%), respiratory tract infection (41%), asthenic conditions (38%), musculoskeletal pain (32%), constipation (30%), nausea (29%), dizziness (27%) and abdominal pain (26%) N 77 73 67 63 55 53 20 10 0 -10 -20 -30 -40 -50 -70 -60 -80 -90 -100 0 12 Weeks24 36 48 60 72 M e a n % C h a n g e f ro m B a s e lin e (S D) Mascarenhas J, et al. ASH 2022. Abstract 238.© MorphoSys – FY 2022 results

------

![](a230316_exhibit992013.jpg)

94 Data Underscore Curative Potential of Tafasitamab in DLBCL 13 ASH 2022: Phase 1b data show no new safety signals and provides additional information on progression-free survival at 24 months\*\*© MorphoSys – FY 2022 results \*Duell J., et al. SOHO 2022. Abstract ABCL-388. \*\*Nowakowski G, et al. ASH 2022. Abstract 1619. DLBCL: diffuse large B-cell lymphoma TAFA/LEN + R-CHOP (n=33)EVENT 94% of patients are alive after 24 months Final five-year efficacy and safety data from L-MIND study will be presented at AACR 2023 during oral presentation SOHO 2022: Phase 2 data suggest tafasitamab can provide long-term treatment efficacy, with durable responses and survival\* 27 of 80 patients (34%) had undergone treatment for at least 2 years, including six who were on treatment for at least 5 years Second-Line DLBCL First-Line DLBCL CR or PR (best response), % 94 24-month PFS rate, % 77 24-month OS rate, % 94 77 94

------

![](a230316_exhibit992014.jpg)

Tulmimetostat Has Potential to Treat Different Advanced Cancers EZH2: enhancer of zeste homolog 2 PTCL: peripheral T-cell lymphoma Potential Use in Array of Advanced Tumors Abnormal EZH2 function is seen in different types of cancer Designed to Improve on First Generation EZH2i Dual inhibitor of EZH2 and EZH1 with best-in-class potential Initial Data from Ongoing Basket Trial Ongoing Phase 1/2 study with anti-tumor responses across patients with ovarian cancer, endometrial cancer, mesothelioma, PTCL 14© MorphoSys – FY 2022 results

------

![](a230316_exhibit992015.jpg)

DLBCL: diffuse large B-cell lymphoma. r/r FL / MZL: relapsed/refractory Follicular Lymphoma or Marginal Zone Lymphoma Rich Set of Pivotal Catalysts Through 2025 15 A S S E T D I S E A S E A R E A S T A T U S Pelabresib (MANIFEST-2) 1L Myelofibrosis Topline data available in early 2024 Tafasitamab (frontMIND) 1L DLBCL Topline data available in H2 2025 Tafasitamab (inMIND) r/r FL / MZL Topline data available in 2024© MorphoSys – FY 2022 results A S S E T D I S E A S E A R E A S T A T U S Ianalumab (Novartis) Sjögren's Syndrome Lupus Nephritis and other autoimmune diseases Development program with several ongoing Phase 3 studies Abelacimab (Anthos Therapeutics) Venous Thromboembolism Prevention Development program with three ongoing Phase 3 studies Setrusumab (Ultragenyx / Mereo BioPharma) Osteogenesis Imperfecta Pivotal Phase 2/3 ongoing clinical study MorphoSys Pivotal Studies Partner Pivotal Studies

------

![](a230316_exhibit992016.jpg)

04 Financial Results & Guidance Sung Lee© MorphoSys – FY 2022 results

------

![](a230316_exhibit992017.jpg)

Monjuvi® U.S. Product Sales and Minjuvi® Royalty Revenue 17 15,5 18,0 22,0 23,6 18,7 23,3 22,2 25,3 0,1 0,7 0,7 0,7 0,9 0,7 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3'22 Q4'22 Royalties from ex-U.S. Sales of Minjuvi U.S. Monjuvi Product Sales USD IN MILLION© MorphoSys – FY 2022 results

------

![](a230316_exhibit992018.jpg)

On December 31, 2022, MorphoSys' liquidity position amounted to € 907.2 million (December 31, 2021: € 976.9 million) Q4 / FY 2022: Profit or Loss Statement© MorphoSys – FY 2022 results 18 in € million Q4 2022 Q4 2021 Δ 2022 2021 Δ Revenues 81.6 52.9 54% 278.3 179.6 55% Product Sales 24.7 20.5 20% 84.9 66.9 27% Royalties 29.1 23.2 25% 99.9 65.6 52% Licenses, Milestones and Other 27.9 9.3 >100% 93.5 47.2 98% Cost of Sales (15.4) (9.5) 62% (48.6) (32.2) 51% Gross Profit 66.2 43.4 53% 229.6 147.4 56% Research and Development (94.0) (87.0) 8% (297.8) (225.2) 32% Selling (23.0) (32.5) (29)% (92.4) (121.5) (24)% General and Administrative (17.5) (18.2) (4)% (60.1) (78.3) (23)% Impairment of Goodwill — (230.7) (100)% — (230.7) (100)% Total Operating Expenses (134.6) (368.4) (63)% (450.4) (655.8) (31)% Operating Profit / (Loss) (68.4) (325.0) (79)% (220.7) (508.3) (57)% Consolidated Net Profit / (Loss) 329.4 (381.0) >(100)% (151.1) (514.5) (71)% Earnings per Share, Basic and Diluted (in €) — (11.16) n/a (4.42) (15.40) (71)% Earnings per Share, Basic 9.64 — n/a — — n/a Earnings per Share, Diluted 8.93 — n/a — — n/a

------

![](a230316_exhibit992019.jpg)

Financial Guidance Full-Year 2023 19 Monjuvi U.S. Net Product Sales US$80m – 95m Gross Margin for Monjuvi U.S. Net Product Sales 75% to 80% R&D Expenses € 290m to 315m SG&A Expenses € 140m to 155m© MorphoSys – FY 2022 results

------

![](a230316_exhibit992020.jpg)

Q&A Tim Demuth, M.D., Ph.D. CR&DO 05 Jean-Paul Kress, M.D. CEO Sung Lee CFO Joe Horvat General Manager, U.S.© MorphoSys – FY 2022 results

------

![](a230316_exhibit992021.jpg)

Thank you! www.morphosys.com© MorphoSys – FY 2022 results

------

![](a230316_exhibit992022.jpg)

3Q 2022 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma© MorphoSys – FY 2022 results 22 We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS. Euros in millions A B C A - B - C differences due to rounding IFRS Incyte Royalty Q3 2022 Collaboration Pharma Revenues 95,8 11,0 28,8 56,0 Monjuvi US product sales 21,9 11,0 1) 11,0 Royalties 29,7 28,8 5) 0,9 Other 44,1 44,1 Cost of Sales (8,1) (1,7) — (6,4) Cost of Sales US Monjuvi product sales (4,5) (1,7) 2) (2,8) Other (3,6) (3,6) Gross Profit 87,7 9,2 28,8 49,6 Gross Margin 91,5% 88,6% Total Operating Expenses: (117,0) (10,8) — (106,2) Research and Development (77,8) (77,8) Selling (23,5) (10.800.000,0) 3) (12,7) General and Administrative (15,6) (15,6) Impairment of Goodwill 0,0 — Operating Profit/(Loss) (29,3) (1,6) 28,8 (56,5) Operating Margin -30,6% -100,9% Other Income 10,6 10,6 Other Expenses (7,5) (7,5) Finance Income 70,3 43,4 4) 12,8 6) 14,1 Finance Expenses (167,5) (15,3) 4) (135,6) 6) (16,6) Income from Reversals of Impairment Losses 0,6 0,6 Income Tax Benefit / (Expenses) 0,1 0,1 Consolidated Net Profit/(Loss) (122,6) 26,5 (94,0) (55,1) EPS, Basic and Diluted (in €) (3,60) (1,61) Shares Used for EPS, Basic and Diluted 34.154.811 34.154.811

------

![](a230316_exhibit992023.jpg)

4Q 2021 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma© MorphoSys – FY 2022 results 23 We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS. Legend 1) Incyte's share of Monjuvi US sales, accounted for at MOR being the principal for this business 2) Incyte's share of cost of sales related to Monjuvi US sales, accounted for at MOR 3) Incyte's portion of Monjuvi US selling expenses, charged to/accounted for at MOR 4) Valuation effects from Incyte financial liability/asset (actual and planning cash flow adjustments, fx effects, interest expense) 5) Tremfya royalty paid to Royalty Pharma from Q2 2021 onward 6) Valuation effects from Royalty Pharma financial liability (actual and planning cash flow adjustments incl. fx effects, interest expense) 7) Write-down results from the consolidation of the Company's research and discovery activities after the acquisition of Constellation Pharmaceuticals, Inc. Euros in millions A B C A - B - C differences due to rounding IFRS Incyte Royalty Q4 2021 Collaboration Pharma Revenues 52,9 10,3 22,6 20,1 Monjuvi US product sales 20,5 10,3 1) 10,3 Royalties 23,2 22,6 5) 0,6 Other 9,3 9,3 Cost of Sales (9,5) (1,6) - (7,9) Cost of Sales US Monjuvi product sales (3,8) (1,6) 2) (2,2) Other (5,7) (5,7) Gross Profit 43,4 8,7 22,6 12,2 Gross Margin 82,0% 60,5% Total Operating Expenses: (368,4) (15,2) - (353,2) Research and Development (87,0) (87,0) Selling (32,5) (15,2) 3) (17,3) General and Administrative (18,2) (18,2) Impairment of Goodwill (230,7) 7) (230,7) Operating Profit/(Loss) (325,0) (6,5) 22,6 (341,0) Operating Margin -614% -1697% Other Income 3,4 3,4 Other Expenses (1,7) (1,7) Finance Income (2,7) (7,7) 4) - 6) 5,0 Finance Expenses (89,0) (16,0) 4) (62,8) 6) (10,2) Effects from Impairment on Financial Assets (0,2) (0,2) Income Tax Benefit / (Expenses) 34,4 34,4 Consolidated Net Profit/(Loss) (380,9) (30,2) (40,2) (310,5) EPS, Basic and Diluted (in €) (11,16) (9,09) EPS, Basic (in €) - - EPS, Diluted (in €) - - Shares Used for EPS, Basic 34.147.495 Shares Used for EPS, Diluted

------

![](a230316_exhibit992024.jpg)

4Q 2022 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma© MorphoSys – FY 2022 results 24 We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS. Euros in millions A B C A - B - C differences due to rounding IFRS Incyte Royalty Q4 2022 Collaboration Pharma Revenues 81,6 12,3 28,4 40,9 Monjuvi US product sales 24,7 12,3 1) 12,3 Royalties 29,1 28,4 5) 0,7 Other 27,9 27,9 Cost of Sales (15,4) (2,1) — (13,3) Cost of Sales US Monjuvi product sales (10,3) (2,1) 2) (8,2) Other (5,1) (5,1) Gross Profit 66,2 10,2 28,4 27,6 Gross Margin 81,1% 67,5% Total Operating Expenses: (134,6) (9,4) — (125,2) Research and Development (94,0) (94,0) Selling (23,0) (9,4) 3) (13,6) General and Administrative (17,5) (17,5) Impairment of Goodwill - — Operating Profit/(Loss) (68,4) 0,8 28,4 (97,6) Operating Margin -83,8% -238,8% Other Income (7,8) (7,8) Other Expenses 7,4 7,4 Finance Income 325,0 312,8 4) 18,4 6) (6,2) Finance Expenses 249,5 44,6 4) 212,3 6) (7,3) Income from Reversals of Impairment Losses 0,4 0,4 Income Tax Benefit / (Expenses) (172,7) (172,7) Share of Loss of Associates accounted for using the Equity Method (4,0) (4,0) Consolidated Net Profit/(Loss) 329,5 358,2 259,1 (287,9) EPS, Basic and Diluted (in €) - (8,43) EPS, Basic (in €) 9,64 - EPS, Diluted (in €) 8,93 - Shares Used for EPS, Basic and Diluted - 34.165.081 Shares Used for EPS, Basic 34.165.081 - Shares Used for EPS, Diluted 36.967.187 -

------

![](a230316_exhibit992025.jpg)

FY 2021 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma© MorphoSys – FY 2022 results 25 We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS. Legend 1) Incyte's share of Monjuvi US sales, accounted for at MOR being the principal for this business 2) Incyte's share of cost of sales related to Monjuvi US sales, accounted for at MOR 3) Incyte's portion of Monjuvi US selling expenses, charged to/accounted for at MOR 4) Valuation effects from Incyte financial liability/asset (actual and planning cash flow adjustments, fx effects, interest expense) 5) Tremfya royalty paid to Royalty Pharma from Q2 2021 onward 6) Valuation effects from Royalty Pharma financial liability (actual and planning cash flow adjustments incl. fx effects, interest expense) 7) Write-down results from the consolidation of the Company's research and discovery activities after the acquisition of Constellation Pharmaceuticals, Inc. Euros in millions A B C A - B - C differences due to rounding IFRS Incyte Royalty FY 2021 Collaboration Pharma Revenues 179,6 33,5 53,2 93,0 Monjuvi US product sales 66,9 33,5 1) 33,5 Royalties 65,6 53,2 5) 12,4 Other 47,2 47,2 Cost of Sales (32,2) (5,2) - (26,8) Cost of Sales US Monjuvi product sales (12,3) (5,2) 2) (7,1) Other (19,7) (19,7) Gross Profit 147,4 28,2 53,2 66,2 Gross Margin 82,1% 71,1% Total Operating Expenses: (655,8) (56,2) - (599,7) Research and Development (225,2) (225,2) Selling (121,6) (56,2) 3) (65,4) General and Administrative (78,4) (78,4) Impairment of Goodwill (230,7) 7) (230,7) Operating Profit/(Loss) (508,4) (27,9) 53,2 (533,5) Operating Margin -283% -574% Other Income 8,3 8,3 Other Expenses (6,3) (6,3) Finance Income 96,6 75,7 4) - 6) 20,9 Finance Expenses (181,5) (59,7) 4) (94,7) 6) (27,1) Effects from Impairment on Financial Assets 0,4 0,4 Income Tax Benefit / (Expenses) 76,6 76,6 Consolidated Net Profit/(Loss) (514,4) (11,9) (41,5) (460,8) EPS, Basic and Diluted (in €) (15,40) (13,80) EPS, Basic (in €) - - EPS, Diluted (in €) - - Shares Used for EPS, Basic 33.401.069 Shares Used for EPS, Diluted

------

![](a230316_exhibit992026.jpg)

FY 2022 Income Statement w/o Incyte 50/50 U.S. Profit Share and Transfers to Royalty Pharma© MorphoSys – FY 2022 results 26 We supplement the consolidated statement of profit or loss presented in our earnings release with additional information on certain income or expense effects. The consolidated statement of profit or loss as well as the additional information in the earnings call slide deck are prepared in accordance with International Financial Reporting Standards (IFRS). The additional information relates to the contracts with Incyte and Royalty Pharma, namely to the accounting for the US co-commercialization with Incyte and the financing provided by Royalty Pharma which resulted in financial liabilities for payments owed to Royalty Pharma in future periods. The related effects are presented in two separate columns for various lines item of the consolidated statement of profit or loss. We believe this more detailed information provides additional insights into the financial performance of MorphoSys Group. The information given is in addition to, not a substitute for, or superior to, the measures of financial performance prepared in accordance with IFRS. Euros in millions A B C A - B - C differences due to rounding IFRS Incyte Royalty FY 2022 Collaboration Pharma Revenues 278,3 42,4 96,9 138,9 Monjuvi US product sales 84,9 42,4 1) 42,4 Royalties 99,9 96,9 5) 3,0 Other 93,5 93,5 Cost of Sales (48,6) (7,2) — (41,5) Cost of Sales US Monjuvi product sales (22,6) (7,2) 2) (15,4) Other (26,1) (26,1) Gross Profit 229,6 35,2 96,9 97,4 Gross Margin 82,5% 70,1% Total Operating Expenses: (450,4) (43,1) — (407,3) Research and Development (297,8) (297,8) Selling (92,4) (43,1) 3) (49,3) General and Administrative (60,1) (60,1) Impairment of Goodwill - — Operating Profit/(Loss) (220,7) (7,9) 96,9 (309,8) Operating Margin -79,3% -223,0% Other Income 12,0 12,0 Other Expenses (15,6) (15,6) Finance Income 412,1 361,4 4) 31,2 6) 19,4 Finance Expenses (165,9) (60,4) 4) (69,6) 6) (35,9) Income from Reversals of Impairment Losses (0,0) (0,0) Income Tax Benefit / (Expenses) (168,6) (168,6) Share of Loss of Associates accounted for using the Equity Method (4,3) (4,3) Consolidated Net Profit/(Loss) (151,1) 293,2 58,5 (502,8) EPS, Basic and Diluted (in €) (4,42) (14,72) EPS, Basic (in €) - - EPS, Diluted (in €) - - Shares Used for EPS, Basic and Diluted 34.155.650 34.155.650 Shares Used for EPS, Basic - - Shares Used for EPS, Diluted - -

------